Biogen Inc.
(NASDAQ : BIIB)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.32%79.980.9%$592.23m
CELGCelgene Corporation
-1.43%136.871.1%$550.43m
AMGNAmgen Inc.
-0.05%186.101.1%$449.62m
BIIBBiogen Inc.
0.11%344.851.2%$386.91m
REGNRegeneron Pharmaceuticals, Inc.
-1.37%436.522.7%$313.61m
ALNYAlnylam Pharmaceuticals, Inc
-1.86%116.4910.7%$251.54m
VRTXVertex Pharmaceuticals Incorporated
-0.41%154.421.9%$220.55m
INCYIncyte Corporation
-0.16%115.452.5%$207.63m
ALXNAlexion Pharmaceuticals, Inc.
-1.89%140.451.9%$178.59m
ILMNIllumina, Inc.
-0.18%206.103.5%$139.62m
EXELExelixis, Inc.
-1.91%27.766.5%$132.85m
CLVSClovis Oncology, Inc.
-3.04%78.8516.5%$120.89m
BLUEBluebird Bio, Inc.
-1.32%138.3517.3%$116.56m
SRPTSarepta Therapeutics, Inc.
-0.35%51.5416.9%$109.64m
BMRNBioMarin Pharmaceutical Inc.
-4.45%89.384.4%$98.89m

Company Profile

Biogen, Inc. is a global biotechnology company, which focuses on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. Its products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, and FAMPYRA for multiple sclerosis, ALPROLIX for hemophilia B and ELOCTATE for hemophilia A. The company also collaborates on the development and commercialization of RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is approved for the treatment of chronic lymphocytic leukemia. Biogen was founded by Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.